title: MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.
abstract: Promoter methylation of the O(6)-methylguanine-DNA-methyltransferase (MGMT) gene has been considered a prognostic marker and has become more important in the treatment of glioblastoma. However, reports on the correlation between MGMT and clinical outcomes in Chinese glioblastoma patients are very scarce. In this study, quantitative methylation data were obtained by the pyrosequencing of tumor tissues from 128 GBM patients. The median overall survival (OS) was 13.1 months, with a 1-year survival of 45.3%. The pyrosequencing data were reproducible based on archived samples yielding data for all glioblastomas. MGMT promoter methylation was detected in 75/128 cases (58.6%), whereas 53/128 (41.4%) cases were unmethylated. Further survival analysis also revealed that methylation was an independent prognostic factor associated with prolonged OS but not with progression-free survival (PFS) (p = 0.029 and p = 0.112, respectively); the hazard radios were 0.63 (95% CI: 0.42-0.96) and 0.72 (95% CI: 0.48-1.09), respectively. These data indicated that MGMT methylation has prognostic significance in patients with newly diagnosed high-grade glioblastoma undergoing alkylating agent-based chemotherapy after surgical resection.
authors.affiliation: Department of Oncology, the Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, P.R. China.
authors.forename: Dong
authors.initials: D
authors.lastname: Shen
authors.affiliation: Department of Oncology, the Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, P.R. China.
authors.forename: Tao
authors.initials: T
authors.lastname: Liu
authors.affiliation: Department of Oncology, the Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, P.R. China.
authors.forename: Qingfen
authors.initials: Q
authors.lastname: Lin
authors.affiliation: Department of Oncology, the Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, P.R. China.
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Lu
authors.affiliation: Department of Oncology, the Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, P.R. China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Department of Oncology, the Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, P.R. China.
authors.forename: Feng
authors.initials: F
authors.lastname: Lin
authors.affiliation: Department of Oncology, the Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, P.R. China.
authors.forename: Weidong
authors.initials: W
authors.lastname: Mao
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D059186:Chemoradiotherapy, Adjuvant; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011401:Promoter Regions, Genetic; D016016:Proportional Hazards Models; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D025521:Tumor Suppressor Proteins; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes